<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ871022-0030 </DOCNO><HL> Praxis Begins Vaccine Studies</HL><DD> 10/22/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> PRXSPHARMACEUTICALS, HOSPITAL SUPPLIES, MANAGEMENT (PHA) </IN><DATELINE> ROCHESTER, N.Y.  </DATELINE><TEXT>   Praxis Biologics Inc. said it initiated phase one of government-approved human clinical studies on its vaccine for respiratory syncytial virus.    The company, which develops purified vaccines for the prevention of medically infectious diseases, said it believes that it is the only company to have received approval from the Food and Drug Administration for clinical studies on a vaccine for the virus.    Respiratory syncytial virus is the world's leading cause of pneumonia and bronchitis in infants two years of age and younger. </TEXT></DOC>